Managed Healthcare Executive October 25, 2019
Drug list prices are increasing at exponential rates. And both Congress, as well as the Trump Administration, have promised to find ways to get curb those costs.
Late last year, for example, the specialty pharmacy industry, as well as the healthcare industry as a whole, was thrown into a tumult when HHS proposed a new rule to eliminate rebates commonly paid by drug manufacturers to Medicare Part D and Medicaid managed care plans, as well as pharmacy benefit managers (PBMs). While the rule has now been abandoned, Congress is currently considering new strategies to revamp Medicare and Medicaid drug plans in order to allow them to remain competitive—and address rising drug costs.
Ross Margulies, JD, MPH, senior associate at Foley...
Today's Sponsors
Today's Sponsor